Americana Partners LLC Acquires 3,169 Shares of Novo Nordisk A/S (NYSE:NVO)

Americana Partners LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 55,100 shares of the company’s stock after buying an additional 3,169 shares during the period. Americana Partners LLC’s holdings in Novo Nordisk A/S were worth $4,740,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Natixis Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC lifted its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $86,000. Talbot Financial LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $4,066,000. Finally, Clear Creek Financial Management LLC purchased a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $450,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 1.1 %

NYSE:NVO opened at $77.94 on Monday. The company has a market cap of $349.75 billion, a P/E ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45. The stock’s fifty day moving average price is $88.65 and its two-hundred day moving average price is $109.70. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts expect that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NVO. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.